Literature DB >> 29220017

Will inter partes review speed US generic drug entry?

Jonathan J Darrow1, Reed F Beall1, Aaron S Kesselheim1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29220017     DOI: 10.1038/nbt.4036

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Updated trends in US brand-name and generic drug competition.

Authors:  Henry Grabowski; Genia Long; Richard Mortimer; Ani Boyo
Journal:  J Med Econ       Date:  2016-04-20       Impact factor: 2.448

  1 in total
  1 in total

1.  Generic Drugs in the United States: Policies to Address Pricing and Competition.

Authors:  Ravi Gupta; Nilay D Shah; Joseph S Ross
Journal:  Clin Pharmacol Ther       Date:  2019-01-10       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.